Get started
Author

Riccardo Ronga

Observed names: R. Ronga, RICCARDO RONGA
ORCID: 0009-0006-8323-3409
Observed ORCID: 0009-0006-8323-3409
OpenAlex ID: A5084588126
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab
2022 · FRANCESCO JACOPO ROMANO, RICCARDO RONGA, et al. · Cancer Diagnosis & Prognosis · 32
PDF
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy
2024 · Vito Longo, Carminia Maria Della Corte, et al. · Frontiers in Immunology · 29
Melasma and reflectance confocal microscopy: from baseline to treatment monitoring
2024 · Stefania Guida, Caterina Longo, et al. · International Journal of Dermatology · 11
PDF
Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy
2022 · Maria Giuseppa Vitale, Anna Crispo, et al. · Frontiers in Pharmacology · 2
PDF
P3.18.18 Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial
2025 · P.M. Medusa, C.M. Della Corte, et al. · Journal of Thoracic Oncology
EP.11.03 First Line Chemo-Immunotherapy Prognostic Factors Predicting Non Small Cell Lung Cancer Overall Survival
2025 · R. Ronga, F. Vitiello, et al. · Journal of Thoracic Oncology
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL
2025 · P.M. Medusa, N. Carro, et al. · Lung Cancer
44P: First-line chemo-immunotherapy prognostic factors predicting non-small cell lung cancer (NSCLC) overall survival: Multicentric observational study
2025 · R. Ronga, F. Vitiello, et al. · Journal of Thoracic Oncology
PDF
13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumab
2021 · F.J. Romano, C. Barbato, et al. · Annals of Oncology
Works count: 10
Citation count: 74
H-index: 3
I10-index: 3
Year
Topic
Type